Dasatinib use was associated with a higher risk of pulmonary arterial hypertension compared with imatinib (1829 vs 43 events per million person-years; HR 8.89; 95% CI 5.30-14.92).
Cohort
Do second- and third-generation BCR-ABL tyrosine kinase inhibitors increase the risk of pulmonary arterial hypertension compared with imatinib in adults with chronic myeloid leukemia?
In patients with chronic myeloid leukemia, dasatinib, bosutinib, and ponatinib are associated with a significantly increased risk of pulmonary arterial hypertension compared with imatinib.
Effect estimate: HR 8.89 (95% CI 5.30-14.92)
Absolute Event Rate: 1829% vs 43%
BACKGROUND: BCR-ABL tyrosine kinase inhibitors (TKIs) have been increasingly linked to pulmonary arterial hypertension (PAH) since 2009, although supporting evidence is limited. Our objective was to evaluate the risk of PAH associated with second- and third-generation BCR-ABL TKIs compared with imatinib in adults. METHODS: We employed a prevalent new-user design that emulates a randomized trial within the French national health care database population between 2008 and 2024. Thus, subjects initiating a second- and third-generation BCR-ABL TKI were matched on time and propensity score with users of the first-generation BCR-ABL TKI, imatinib. Patients were followed to occurrence of the primary outcome (ie, new onset of PAH), switch to another BCR-ABL TKI, death from any cause, end of registration within the database, or end of the study period, whichever came first. Hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards regression models, and incidence rates and corresponding 95% CIs were calculated using the Poisson distribution. RESULTS: Six thousand six hundred twenty-five dasatinib (age 59.7±15.2 years, 44.0% women), 5205 nilotinib (age 55.4±15.0 years, 44.2% women), 2421 bosutinib (age 63.8±14.2 years, 42.1% women),1358 ponatinib (age 57.3±14.9 years, 46.1% women), and 922 asciminib (age 64.3±13.8 years, 43.7% female) new users were each matched with the maximum of available imatinib users on time-conditional propensity score and on duration of prior imatinib use (prevalent users). Dasatinib use was associated with a 9-fold increased risk of PAH compared with imatinib (1829 versus 43 events per million persons per year; HR=8.89 95% CI, 5.30–14.92). Bosutinib and ponatinib were associated with HRs of 10.76 (95% CI, 4.68–24.73) and 7.74 (95% CI, 2.33–25.70) respectively, with most cases occurring in patients previously exposed to dasatinib. Nilotinib and asciminib were not associated with an increased risk of PAH. CONCLUSION: This study, designed to emulate a randomized trial, suggests that, in French patients with chronic myeloid leukemia treated with BCR-ABL TKIs, dasatinib use is associated with a higher risk of PAH compared with imatinib, while bosutinib and ponatinib exposure may aggravate or trigger a recurrence of PAH in patients with preexisting dasatinib exposure. Whether bosutinib and ponatinib could induce PAH without preexposure to dasatinib remains to be explored.
Jambon-Barbara et al. (Thu,) conducted a cohort in Chronic myeloid leukemia. Second- and third-generation BCR-ABL TKIs (dasatinib, nilotinib, bosutinib, ponatinib, asciminib) vs. Imatinib was evaluated on New onset of pulmonary arterial hypertension (PAH) (HR 8.89, 95% CI 5.30-14.92). Dasatinib use was associated with a higher risk of pulmonary arterial hypertension compared with imatinib (1829 vs 43 events per million person-years; HR 8.89; 95% CI 5.30-14.92).